Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


07.10.2019

1 Am J Respir Cell Mol Biol
1 Ann Surg Oncol
2 Ann Thorac Surg
4 Anticancer Res
1 Br J Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
2 Cancer Res
3 Cancer Sci
2 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cancer
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Natl Cancer Inst
2 J Thorac Cardiovasc Surg
4 J Thorac Oncol
1 Lancet Oncol
4 Lung Cancer
1 Lung Cancer (Auckl)
1 Mol Carcinog
2 N Engl J Med
3 Oncogene
1 Oncol Rep
4 PLoS One
1 Semin Oncol
2 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Cell Mol Biol

  1. MARHUENDA E, Campillo N, Gabasa M, Martinez-Garcia MA, et al
    Effects of Sustained and Intermittent Hypoxia on Human Lung Cancer Cells.
    Am J Respir Cell Mol Biol. 2019;61:540-544.
    PubMed     Text format    


    Ann Surg Oncol

  2. NAKAZAWA N, Yokobori T, Kaira K, Turtoi A, et al
    High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors.
    Ann Surg Oncol. 2019 Sep 30. pii: 10.1245/s10434-019-07878.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  3. BHAGAT R, Bronsert MR, Henderson WG, Scott CD, et al
    Analysis of Discharge Destination after Open vs. Minimally Invasive Surgery for Lung Cancer.
    Ann Thorac Surg. 2019 Sep 30. pii: S0003-4975(19)31450.
    PubMed     Text format     Abstract available

  4. WEI YC, Gao HJ
    Sleeve lobectomy for centrally located non-small cell lung cancer: does incision size really matter? (Reply).
    Ann Thorac Surg. 2019 Sep 30. pii: S0003-4975(19)31456.
    PubMed     Text format    


    Anticancer Res

  5. NASU S, Okamoto N, Suzuki H, Shiroyama T, et al
    Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer.
    Anticancer Res. 2019;39:5683-5688.
    PubMed     Text format     Abstract available

  6. CHEN GL, Wang SC, Huang WC, Chang WS, et al
    The Association of MMP-11 Promoter Polymorphisms With Susceptibility to Lung Cancer in Taiwan.
    Anticancer Res. 2019;39:5375-5380.
    PubMed     Text format     Abstract available

  7. ZHANG Q, Song Y, Cheng X, Xu Z, et al
    Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
    Anticancer Res. 2019;39:5461-5471.
    PubMed     Text format     Abstract available

  8. NAKAO S, Yamaguchi K, Sakamoto S, Horimasu Y, et al
    Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
    Anticancer Res. 2019;39:5725-5731.
    PubMed     Text format     Abstract available


    Br J Cancer

  9. LEONETTI A, Sharma S, Minari R, Perego P, et al
    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Br J Cancer. 2019 Sep 30. pii: 10.1038/s41416-019-0573.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  10. SCHABATH MB, Cote ML
    Cancer Progress and Priorities: Lung Cancer.
    Cancer Epidemiol Biomarkers Prev. 2019;28:1563-1579.
    PubMed     Text format    


    Cancer Lett

  11. REDA M, Ngamcherdtrakul W, Gu S, Bejan DS, et al
    PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30486.
    PubMed     Text format     Abstract available

  12. HAMMAD A, Namani A, Elshaer M, Wang XJ, et al
    "NRF2 Addiction" in Lung Cancer Cells and Its Impact on Cancer Therapy.
    Cancer Lett. 2019 Sep 28. pii: S0304-3835(19)30488.
    PubMed     Text format     Abstract available


    Cancer Res

  13. DONG SH, Li W, Wang L, Hu J, et al
    Histone-related genes are hypermethylated in lung cancer and hypermethylated HIST1H4F could serve as a pan-cancer biomarker.
    Cancer Res. 2019 Oct 1. pii: 0008-5472.CAN-19-1019.
    PubMed     Text format     Abstract available

  14. BOWCOCK AM
    A Breath of Fresh Air: Opening up the Lung Cancer Genome.
    Cancer Res. 2019;79:4808-4810.
    PubMed     Text format     Abstract available


    Cancer Sci

  15. WANG L, Liang Y, Mao Q, Xia W, et al
    Circular RNA circCRIM1 inhibits invasion and metastasis in lung adenocarcinoma through the microRNA (miR)-182/miR-93-leukemia inhibitory factor receptor pathway.
    Cancer Sci. 2019;110:2960-2972.
    PubMed     Text format     Abstract available

  16. YOSHIMOTO T, Matsubara D, Soda M, Ueno T, et al
    Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocarcinoma.
    Cancer Sci. 2019;110:3006-3011.
    PubMed     Text format     Abstract available

  17. SHINCHI Y, Komohara Y, Yonemitsu K, Sato K, et al
    Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Cancer Sci. 2019;110:2711-2721.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  18. DUMA N, Idossa DW, Durani U, Frank RD, et al
    Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 Aug 30. pii: S1525-7304(19)30254.
    PubMed     Text format     Abstract available

  19. AGULLO-ORTUNO MT, Gomez-Martin O, Ponce S, Iglesias L, et al
    Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
    Clin Lung Cancer. 2019 Aug 30. pii: S1525-7304(19)30255.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  20. ZHANG GX, Zheng Y, Huang WS, Yang M, et al
    FDG PET/CT Findings of Unsuspected Pulmonary Epithelioid Angiosarcoma Manifested as a Brain Metastasis.
    Clin Nucl Med. 2019;44:e489-e491.
    PubMed     Text format     Abstract available


    Eur J Cancer

  21. VISSER S, Koolen SLW, de Bruijn P, Belderbos HNA, et al
    Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
    Eur J Cancer. 2019;121:64-73.
    PubMed     Text format     Abstract available


    Int J Cancer

  22. DAI J, Huang M, Amos CI, Hung RJ, et al
    Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32698.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  23. OHNISHI K, Nakamura N, Harada H, Tokumaru S, et al
    Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
    Int J Radiat Oncol Biol Phys. 2019 Sep 30. pii: S0360-3016(19)33837.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  24. KATKI HA, Cheung LC, Landy R
    Basing eligibility for lung cancer screening on individualized risk calculators should save more lives, but life-expectancy matters.
    J Natl Cancer Inst. 2019 Sep 30. pii: 5578424. doi: 10.1093.
    PubMed     Text format    

  25. TEN HAAF K, Bastani M, Cao P, Jeon J, et al
    A comparative modeling analysis of risk-based lung cancer screening strategies.
    J Natl Cancer Inst. 2019 Sep 30. pii: 5578423. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  26. OKAMURA A, Watanabe M, Hayami M, Mine S, et al
    Esophagectomy via upper partial sternotomy for esophageal cancer after previous right pneumonectomy: A case report.
    J Thorac Cardiovasc Surg. 2018;156:e217-e220.
    PubMed     Text format    

  27. OKADA M, Miyata Y, Takamochi K, Tsutani Y, et al
    Prospective feasibility study of sealing pulmonary vessels with energy in lung surgery.
    J Thorac Cardiovasc Surg. 2019;157:388-395.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  28. GRANNIS FW JR
    Lung Cancer Incidence and Mortality with Extended Follow-up during Screening.
    J Thorac Oncol. 2019;14:1692-1694.
    PubMed     Text format    

  29. ARRIETA O, Zatarain-Barron ZL, Aldaco F, Barron F, et al
    Lung Cancer in Mexico.
    J Thorac Oncol. 2019;14:1695-1700.
    PubMed     Text format    

  30. GUAN R, Lin A, Luo P, Zhang J, et al
    Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e222-e224.
    PubMed     Text format    

  31. SANCHIS-BORJA M, Parrot A, Sroussi D, Rivin Del Campo E, et al
    Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer.
    J Thorac Oncol. 2019;14:e224-e226.
    PubMed     Text format    


    Lancet Oncol

  32. FIERO MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, et al
    US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.
    Lancet Oncol. 2019;20:e582-e589.
    PubMed     Text format     Abstract available


    Lung Cancer

  33. YOSHIMURA A, Yamada T, Miyagawa-Hayashino A, Sonobe Y, et al
    Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
    Lung Cancer. 2019;137:108-112.
    PubMed     Text format     Abstract available

  34. GELATTI ACZ, Drilon A, Santini FC
    Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;137:113-122.
    PubMed     Text format     Abstract available

  35. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9].
    Lung Cancer. 2019;136:156.
    PubMed     Text format    

  36. MURTHY V, Katzman DP, Tsay JJ, Bessich JL, et al
    Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
    Lung Cancer. 2019;137:94-99.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  37. NAGASAKA M, Abdallah N, Crosby M, Thummala N, et al
    A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors.
    Lung Cancer (Auckl). 2019;10:95-105.
    PubMed     Text format     Abstract available


    Mol Carcinog

  38. TSUBOI M, Kondo K, Soejima S, Kajiura K, et al
    Chromate exposure induces DNA hypermethylation of the mismatch repair gene MLH1 in lung cancer.
    Mol Carcinog. 2019 Oct 3. doi: 10.1002/mc.23125.
    PubMed     Text format     Abstract available


    N Engl J Med

  39. GARRIDO-ABAD P, Garcia-Martin L
    Vocal Cord Metastasis.
    N Engl J Med. 2019;381:e18.
    PubMed     Text format    

  40. HELLMANN MD, Paz-Ares L, Bernabe Caro R, Zurawski B, et al
    Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910231.
    PubMed     Text format     Abstract available


    Oncogene

  41. SALAMA MF, Liu M, Clarke CJ, Espaillat MP, et al
    Correction: PKCalpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
    Oncogene. 2019 Oct 1. pii: 10.1038/s41388-019-1019.
    PubMed     Text format     Abstract available

  42. SINGH K, Pruski MA, Polireddy K, Jones NC, et al
    Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.
    Oncogene. 2019 Sep 30. pii: 10.1038/s41388-019-1031.
    PubMed     Text format     Abstract available

  43. HSU YL, Huang MS, Hung JY, Chang WA, et al
    Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer.
    Oncogene. 2019 Sep 26. pii: 10.1038/s41388-019-1024.
    PubMed     Text format     Abstract available


    Oncol Rep

  44. LI Z, Wang Y, Wu L, Dong Y, et al
    Apurinic endonuclease 1 promotes the cisplatin resistance of lung cancer cells by inducing Parkinmediated mitophagy.
    Oncol Rep. 2019 Oct 1. doi: 10.3892/or.2019.7345.
    PubMed     Text format     Abstract available


    PLoS One

  45. MITSUYA K, Nakasu Y, Hayashi N, Deguchi S, et al
    Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.
    PLoS One. 2019;14:e0210074.
    PubMed     Text format     Abstract available

  46. ZHANG H, Chen J, Liu T, Dang J, et al
    First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
    PLoS One. 2019;14:e0223530.
    PubMed     Text format     Abstract available

  47. HUA X, Han SH, Wei SZ, Wu Y, et al
    Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.
    PLoS One. 2019;14:e0223230.
    PubMed     Text format     Abstract available

  48. SHAO B, Bjaanaes MM, Helland A, Schutte C, et al
    EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.
    PLoS One. 2019;14:e0204186.
    PubMed     Text format     Abstract available


    Semin Oncol

  49. MASOOD A, Kancha RK, Subramanian J
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Semin Oncol. 2019 Sep 11. pii: S0093-7754(18)30191.
    PubMed     Text format     Abstract available


    Thorax

  50. RUPAREL M, Quaife SL, Dickson JL, Horst C, et al
    Evaluation of cardiovascular risk in a lung cancer screening cohort.
    Thorax. 2019 Sep 26. pii: thoraxjnl-2018-212812.
    PubMed     Text format     Abstract available

  51. FISK M, Bolton CE
    Is targeted lung cancer screening an opportune time to address cardiovascular risk?
    Thorax. 2019 Sep 26. pii: thoraxjnl-2019-213790.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: